Compare AbbVie Inc (ABBV) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Jumia Technologies AG - ADR — how do they compare? AbbVie Inc trades at $249.9 (market cap $441.94B), while Jumia Technologies AG - ADR trades at $6.15 (market cap $719.58M). The key difference: AbbVie Inc is far larger — about 614.2× Jumia Technologies AG - ADR's market cap, and AbbVie Inc pays a 2.77% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| ABBV | JMIA | |
|---|---|---|
Market Cap | $441.94B | $719.58M |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $14.60 |
52-Week Low | $197.38 | $5.69 |
Enterprise Value | $506.19B | $666.68M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
JMIA trades at $6.00, down 3.07% today, with a bearish technical signal. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses, though it remains unprofitable with a -30.79% net margin. Analyst sentiment is positive with 71% buy ratings, supported by progress toward Q4 2026 breakeven targets and recent $50M capital raise.
The path to profitability remains the key investment thesis, with management targeting 2027 EBITDA breakeven. Risks include persistent cash burn, competitive e-commerce landscape, and execution challenges in African markets. The stock offers speculative upside if turnaround continues but carries significant operational risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
